Диссертация (Анализ применения фармакогенетического тестирования для индивидуализации применения пероральных антикоагулянтов и статинов у пациентов терапевтического профиля в условиях функционирования центра персонализированной медицины), страница 26

2004. - Vol. 364. - P. 685-696.36.Creswell L.L., Schuessler R.B., Rosenbloom M., Cox J.L. Hazards of postoperativeatrial arrhythmias. Ann Thorac Surg 1993; 56 (3):539—549.37.D'Andrea G. et al. A polymorphism in the VKORC1 gene is associated with aninterindividual variability in the dose-anticoagulant effect of warfarin //Blood. – 2005;105(2):645-649.38.Davidson M, McKenney J, Stein E, et al. Comparison of one-year efficacy and safetyof atorvastatin versus lovastatin in primary hyper-cholesterolemia. Atorvastatin StudyGroup I. Am J Cardiol 1997;79: 1475-81.39.De Keyser C.E., Peters B.J., Becker M.L., Visser L.E., Uitterlinden A.G., KlungelO.H.

et al. The SLCO1B1 c.521T>C polymorphism is associated with dose decrease orswitching during statin therapy in the Rotterdam Study. Pharmacogenet Genomics. 2014;24 (1): 43–51.40.De Lorgeril M., Salen P., Bontemps L. et al. Effects of lipid-lowering drugs on leftventricular function and exercise tolerance in dyslipidemic coronary patients. J CardiovascPharmacol 1999; 33:473-841.De Pinieux G, Chariot P, Ammi-Said M, et al. Lipid-lowering drugs andmitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone andblood lactate/pyruvate ratio. Br J Clin Pharmacol 1996; 42:333-7.13342.Diebold BA, Bhagavan NV, Guillory RJ.

Influences of lovastatin administration onthe respiratory burst of leukocytes and the phosphorylation potential of mitochondria inguinea pigs. Biochim Biophys Acta 1994; 1200:100-843.Donnelly L.A., Doney A.S., Dannfald J. et al. A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment indiabetes: a GoDARTS study // Pharmacogenet. Genomics. - 2008. - Vol.

18. - P. 1021-1026.44.Dou Y, Zhu X, Wang Q, Tian X, Cheng J, Zhang E. Meta-Analysis of the SLCO1B1c.521T>C Variant Reveals Slight Influence on the Lipid-Lowering Efficacy of Statins. AnnLab Med. 2015 May;35(3):329-35.45.Dowlatshahi D, Butcher KS, Asdaghi N et al. Poor prognosis in warfarin-associatedintracranial hemorrhage despite anticoagulation reversal. Stroke. 2012; 43:1812–1817.46.Downs J.R., Clearfield M., Weis S. et al. Primary prevention of acute coronary eventswith lovastatin in men and women with average cholesterol levels // JAMA.

- 1998. - Vol.279. - P. 1615-1622.47.EAFT Group Secondary prevention in nonrheumatic atrial fibrillation after transientischaemic attack or minor stroke. Lancet 1993;342:1255–62.48.Ederhy S, Cohen A.et al. Optimising stroke prevention in non-valvular atrialfibrillation. Expert Opion Pharmacotherapy: 2006;7(15):2079-209449.Eisen S.A., Miller D.K., Woodward R.S. et al.

The effect of prescribed daily dosefrequency on patient medication compliance. Arch Intern Med. 1990. Vol. 150. Р. 1881–1884.).50.Eitz T., Schenk S., Fritzsche D. et al. Self-control of international normalized ratiohelps reduce the risk of thromboembolic complications after heart valve replacement. Ann.Thorac. Surg. 2008; 85: 949—955. 12.7.51.El-Salem K., Ababeneh B., Rudnicki S., et al. Prevalence and risk factors of musclecomplications secondary to statins. Muscle Nerve 2011; 44:877— 881.52.Erdoran O.

Risk assessment and therapy decision in patients at low risk for stroke:CHA2DS2-VASc vs CHADS2. Eur. Heart J. 2013; 34:168-169.53.ESC Guidelines. Guidelines for the management of atrial fibrillation. Eur Heart J2010; 31: 2369-429.13454.European Stroke Organisation (ESO) Executive Committee; ESO WritingCommittee. Guidelines for management of ischaemic stroke and transient ischaemic attack.Cerebrovasc Dis 2008; 25:457–507.55.Ezekowitz M.D. et al. Dabigatran compared with warfarin in patients with atrialfibrillation and previous transient ischemic attack or stroke: a subgroup analysis of the RELY trial.

Lancet Neurol 2010; 9:1157–63.56.Ezekowitz M.D., Bridgers S.L., Javes K.E. et al. Warfarin in the prevention of strokeassociated with nonrheumatic atrial fibrillation. NEJM 1992; 327: 1406– 141357.FDA Drug Safety Communication: New restrictions, contraindications, and doselimitationsforZocor(simvastatin)toreducetheriskofmuscleinjury.http://www.fda.gov/drugs/drugsafety/ucm256581.htm (дата обращения 01.03.2016).58.Ferder N. S., Eby C. S., Deych E. A. et al.

Ability of VKORC1 and CYP2C9 to predicttherapeutic warfarin dose during the initial weeks of therapy. J. Thromb. Haemost. 2010; 8:95-100.59.Folkers K, Langsjoen P, Willis R, et al. Lovastatin decreases coenzyme Qlevels inhumans. Proc Natl Acad Sci U S A 1990; 87:8931-4.60.Ford E.

S., Capewell S. Proportion of the decline in cardiovascular mortality diseasedue to prevention versus treatment: public health versus clinical care //Annual review ofpublic health. – 2011. – Т. 32. – С. 5-22.61.Fox CS, Parise H, D'Agostino RB, et al. (June 2004). «Parental atrial fibrillation as ariskfactorforatrialfibrillationinoffspring».JAMA291(23):2851–5.DOI:10.1001/jama.291.23.2851.

PMID 15199036.62.Freedman MD (March 1992). «Oral anticoagulants: pharmacodynamics, clinicalindications and adverse effects». J Clin Pharmacol 32 (3): 196–209. PMID 1564123.63.Friberg J., Buch P., Scharling H, et al. (November 2003). «Rising rates of hospitaladmissionsforatrialfibrillation».Epidemiology14(6):666–72.DOI:10.1097/01.ede.0000091649.26364.c0. PMID 14569181.64.Frost L, Hune LJ, Vestergaard P. (2005). «Overweight and obesity as risk factors foratrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study».

Am J Med 118 (5):489—95. PMID 15866251.13565.Fu R., Wu S., Wu P. et al. A study of blood soluble P-selectin, fibrinogen, and vonWillebrand factor levels in idiopathic and lone atrial fibrillation // Europace. – 2011. –Vol.13. – P.31-36.66.Fukami M, Maeda N, Fukushige J, et al. Effects of HMG-CoA reductase inhibitorson skeletal muscles of rabbits. Res Exp Med (Berl) 1993; 193:263-73.67.Furberg C.D., Psaty B.M., Manolio T.A., et al.

(August 1994). «Prevalence of atrialfibrillation in elderly subjects (the Cardiovascular Health Study) ». Am. J. Cardiol. 74 (3):236–41. PMID 8037127.68.Furie K.L., Kasner S.E., Adams R.J. et al. Guidelines for the Prevention of Stroke inPatients With Stroke or Transient Ischemic Attack A Guideline for Healthcare ProfessionalsFrom the American Heart Association/American Stroke Association. Stroke 2011; 42:227–76.69.Gage B.F., Cardinalli A.B., Owens D.K. The effect of stroke and stroke prophylaxiswith aspirin or warfarin on quality of life. // Arch Intern Med., 1996; 156:1829–1836.70.Gage B.F., Waterman A.D., Shannon W.

et al. Validation of clinical classificationschemes for predicting stroke: results from the National Registry of Atrial Fibrillation.JAMA 2001; 285:2864–70.71.Gami A.S., Hodge D.O., Herges R.M., et al. (February 2007). «Obstructive sleepapnea, obesity, and the risk of incident atrial fibrillation». J. Am. Coll.

Cardiol. 49 (5): 565–71. Doi: 10.1016/j.jacc.2006.08.060. PMID 17276180.72.Geisen C., Watzka M., Sittinger K. et al. VKORC1 haplotypes and their impact onthe interindividual and interethnical variability of oral anticoagulation. Thromb Haemost.2005; 94 (4): 773-7799.73.Ghirlanda G., Oradei A., Manto A., et al.

Evidence of plasma CoQ10-lowering effectby HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J ClinPharmacol 1993; 33:226-9.74.Glueck C. J. et al. Vitamin D deficiency, myositis–myalgia, and reversible statinintolerance. Current medical research and opinion. 2011; 27(9):1683-1690.75.Go A.S., Hylek E.M., Phillips K.A., et al.

(May 2001). Prevalence of diagnosed atrialfibrillation in adults: national implications for rhythm management and stroke prevention:136the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study». JAMA 285(18): 2370–5. PMID 11343485.76.Gorin I. et al. Antithrombotic treatment and the risk of death and stroke in patientswith atrial fibrillation and a CHADS2 score =1.

Thromb Haemost, 2009; 103: 833–84077.Gorter J.W. for the Stroke Prevention In Reversible Ischemia Trial (SPIRIT) andEuropean Atrial Fibrillation Trial (EAFT) study groups. «Major bleeding duringanticoagulation after cerebral ischemia: patterns and risk factors» Neurology 1999;53:1319–132778.Guyatt G.H., Akl E.A., Crowther M.

et al. Executive summary: Antithrombotictherapy and prevention of thrombosis, 9th ed.: American College of Chest PhysiciansEvidence-Based Clinical Practice Guidelines Chest. 2012; 141(2):7-47.79.Habara S., Dote K., Kato M., et al. Prediction of left atrial appendage thrombi in non-valvular atrial fibrillation Eur.

Heart J. 2007; 28:2217-222280.Hart R.G., Benavente O., McBride R., et al. Antithrombotic therapy to prevent strokein patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131: 492–501.81.Hart R.G., Tonarelli S.B., Pearce L.A. Avoiding Central nervous system bleedingduring antithrombotic therapy. Recent Data and Ideas. Stroke. 2005;36: 1588–1593.82.Heeringa J., van der Kuip D.A., Hofman A. et al. Prevalence, incidence and lifetimerisk of atrial fibrillation: The Rotterdam study Eur.

Heart J. 2006; 27:949-953.83.Heneghan C., et al. Self-monitoring of oral anticoagulation: a systematic review andmeta-analysis. The Lancet. 2006; 367(9508):404-411.84.Herman D., Locatelli I., Grabnar I., et al. Influence of CYP2C9 polymorphisms,demographic factors and concomitant drug therapy on warfarin metabolism andmaintenance dose. J. Pharmacogenomics. In press 2005; 5:193–202.85.Higashi, M.K., et al Association between CYP2C9 genetic variants andanticoagulation-related outcomes during warfarin therapy. JAMA. 2002; 287(13):16901698.86.Hirsh J., Fuster V., Ancell J., et al.

ACC/AHA/ Foundation guide to warfarin therapy.Circulation 2003; 107: 1692—1711.13787.Hjermann I., et al. Effect of diet and smoking intervention on the incidence ofcoronary heart disease: report from the Oslo Study Group of a randomised trial in healthymen The Lancet. 1981; 318(8259):1303-1310.88.Holbrook A. M., Pereira J. A., Labiris R. A. et al.